Hims & Hers (NYSE: HIMS) stock was a heartening comeback story on Wednesday, following something of a rout earlier in the ...
Hims & Hers stock drops 26% as FDA resolves semaglutide shortage, threatening GLP-1 revenue. Click here to find out why HIMS ...
Hims & Hers Health reported fourth-quarter revenue of $481.14 million, beating estimates of $470.31 million, according to ...
Telehealth pioneer Hims & Hers Health (HIMS) stock is soaring, with a 12% gain in recent days and a whopping 176% in the last ...
Stock in Hims & Hers Health was bound to tumble once it [could no longer sell]( ...
Shares of Hims & Hers Health ( HIMS -25.79%) are falling on Friday. The company's stock lost 23.2% as of 1 p.m. ET and lost ...
Hims & Hers Health, Inc. showcases strong growth with diverse revenue streams. Discover why its stock dip offers a unique opportunity. Learn more on HIMS stock here.
Hims & Hers Health reports its fourth-quarter results after Monday's closing bell. Here's a look at the key figures from the ...
San Francisco, CA-based Hims & Hers Health, Inc. is a consumer-centric health and wellness platform that redefines healthcare through personalized solutions and seamless digital access.
Hims and Hers Health Inc. (HIMS) produced sterling results on Feb. 24, spurring huge interest in HIMS call options trading.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback